Clinical Trials Directory

Trials / Unknown

UnknownNCT05197205

Nasopharyngeal Bacterial Carriage and Antibiotic Resistance in Children With Sickle Cell Disease in Ile-De-France

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
600 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
6 Months – 15 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to to determine the rate of nasopharyngeal carriage of Streptococcus pneumoniae (Sp) in children with sickle cell disease over 6 months and under 15 years of age over a 9-month period in Ile-De-France.

Detailed description

Sickle cell disease is the most common genetic disease in France, with one affected child for every 1,736 births. Ile-de-France is the region in Europe with the highest prevalence of sickle cell disease. Children with sickle cell disease have an increased susceptibility to infections related to encapsulated bacteria and are at high risk of invasive infections (particularly Streptococcus pneumoniae), which is the leading cause of mortality in children with sickle cell disease under 5 years of age worldwide. the patients are subject to intense selection pressure (long-term antibiotic prophylaxis and systematic probabilistic curative antibiotic therapy) and are at high risk of carrying nosocomial bacteria (repeated hospitalizations). Moreover, children with sickle cell disease have reinforced immunization schedules, especially against pneumococcal disease. However, data concerning the carriage of resistant bacteria (prevalence, risk factors) in children with sickle cell disease in France are scarce. This study aims to determine the nasopharyngeal bacterial carriage and antibiotic resistance in children with sickle cell disease in Ile-De-France

Conditions

Interventions

TypeNameDescription
PROCEDUREnasopharyngeal swabbingA nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study

Timeline

Start date
2022-02-01
Primary completion
2022-02-01
Completion
2023-02-01
First posted
2022-01-19
Last updated
2022-01-19

Source: ClinicalTrials.gov record NCT05197205. Inclusion in this directory is not an endorsement.